RIO DE JANEIRO, BRAZIL - The UN agency UNITAID on Friday announced the rollout of an allegedly highly effective, long-acting injectable HIV preventive treatment in South Africa and Brazil through two large-scale operational projects funded by the global health agency.
It is an injectable version of pre-exposure prophylaxis (PrEP) that has been found to be more effective than daily oral PrEP in reducing the risk of HIV infection, with just six injections a year.
The injection, whose active ingredient is cabotegravir, is developed by ViiV Healthcare and approved by the US health authority. It offers two months of . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here